Erythropoiesis Stimulating Agents (ESAs): Aranesp (darbepoetin alfa), Epogen (epoetin alfa), and Procrit (epoetin alfa)
admin March 14th, 2008
The FDA have issued warnings related to Erythropoiesis Stimulating Agents (ESAs):
Increased Mortality and/or Tumor Progression section of the Aranesp and EPOGEN/PROCRIT labeling to update information describing the results of two additional studies showing increased mortality and more rapid tumor progression in patients with cancer receiving ESAs. Based on the results of these studies, the prescribing information has been revised as follows: ESAs shortened overall survival and/or time to tumor progression in clinical studies in patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers when dosed to target a hemoglobin of ≥ 12 g/dL.
- FDA
- Comments Off